Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lenalidomide + metronomic cyclophosphamide + prednisone in newly diagnosed multiple myeloma patients older than 75 years
2008-006868-11Phase 2Active
- Sponsor
- Asociación Andaluza de Hematología y Hemoterapia
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by Asociación Andaluza de Hematología y Hemoterapia. Primary endpoint: stringent complete response rate. Started Nov 2008; status: active.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-006868-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006868-11.